Therapy News and Research

RSS

Patheon, Dendreon announce signing of technology transfer agreement

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE (sipuleucel-T) manufacturing process.

6 Aug 2010

Nanosphere reports net loss of $13.8M for second-quarter 2010

Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the second quarter ended June 30, 2010.

6 Aug 2010

WaferGen launches SmartChip System for discovery, validation of biomarkers

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced it has launched the breakthrough WaferGen SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

6 Aug 2010

Incyte second-quarter total revenues increase to $49.8 million

Incyte Corporation today reported second quarter 2010 financial results and described progress for several of its clinical programs.

5 Aug 2010

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

5 Aug 2010

$Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer$

Aeterna Zentaris announces $1.5M NIH award for AEZS-108 Phase 1/2 study in refractory prostate cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health ("NIH") has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase 1/2 study in refractory prostate cancer with the Company's doxorubicin LHRH receptor targeted conjugate compound, AEZS-108.

5 Aug 2010

New article highlights importance of patient safety features in design of IV needleless connectors

A new article by infection control expert William Jarvis, M.D., President, Jason and Jarvis Associates, LLC, highlights the importance of patient safety features in the design of IV needleless connectors.

5 Aug 2010

New volume on Growth hormone therapy

Growth hormone (GH) has been used therapeutically for over 50 years. Since the development of a nearly unlimited supply of recombinant human GH in the mid-1980s, children with less severe GH deficiency can also profit from GH replacement therapy.

5 Aug 2010

CEL-SCI produces and fills first lot of Multikine

CEL-SCI Corporation announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer.

5 Aug 2010

TCA Cellular Therapy enrolls first patient for adult stem cell clinical trial

TCA Cellular Therapy, LLC has enrolled its first patient to participate in the U.S. Food and Drug Administration (FDA) first adult stem cell clinical trial to treat spinal cord injuries. Enrollee and Marine Veteran, Matt Cole was paralyzed from the chest down in a 2005 insurgent attack in Iraq.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Hayfever: time we moved exams to the winter?

Crucial exams take place during adolescence in most societies, which can have a major impact on an individual’s career trajectory. In a Guest Editorial appearing in the August issue of Expert Review of Respiratory Medicine, a team of UK experts review the evidence of the disease burden associated with hayfever and summarize recent evidence suggesting that poorly controlled hayfever can adversely impact on exam performance.

5 Aug 2010

Healing Touch helps to restore normal energy balance

Greenwich Hospital surgical, labor and delivery, and oncology patients are among those who have received a healing boost through a form of energy therapy known as Healing Touch.The hospital, known for its reputation of service excellence, is among a growing number of medical facilities utilizing Healing Touch, which is a gentle, noninvasive therapy shown to facilitate the relaxation response to enhance the healing process. Research shows that, in addition to inducing a deep sense of calm and relaxation, Healing Touch helps to reduce pain, decrease anxiety, promote sleep and improve an overall sense of well-being.

5 Aug 2010

Neurobiologists discover potential cure for degenerative vision diseases

Neurobiologists funded by the Office of Naval Research have discovered a potential cure for degenerative vision diseases leading to terminal blindness.

5 Aug 2010

University of Pennsylvania announces recipients of 2010 Templeton Positive Neuroscience Awards

The Positive Psychology Center of the University of Pennsylvania and the John Templeton Foundation have announced the recipients of the 2010 Templeton Positive Neuroscience Awards, $2.9 million given to 15 new research projects at the intersection of neuroscience and positive psychology.

5 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

Scientists analyze new technique to quickly identify particular asthma subtypes

For many people afflicted by asthma, treatment can be a frustrating and time-consuming experience. After their initial diagnosis, asthmatics find themselves caught in a trial and error process that can last for months, as doctors gradually escalate their medications to treat their condition effectively with minimal side effects. And until the right medicine and dosage are found, patients continue to suffer attacks that strike without warning and can leave them struggling for breath for hours or even days.

5 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

NanoBio Corporation receives U.S. patent for nanoemulsion technology

NanoBio Corporation announced today that it has been awarded a seventh U.S. patent covering its novel nanoemulsion technology. The new claims encompass methods of treating Herpes Simplex I infections, including herpes labialis (commonly referred to as cold sores), using NanoBio's proprietary anti-infective nanoemulsion product candidates.

5 Aug 2010

Ferroportin levels are strong predictors of propensity for breast cancer recurrence: Study

A new study by researchers at Wake Forest University Baptist Medical Center (WFUBMC) may soon help to spare some women with breast cancer from having to undergo invasive and toxic treatments for their disease.

5 Aug 2010